Skip to content

Assessing the safety and effectiveness of the BariClip device in the treatment of severe obesity in Jordan

Assessing weight loss, adverse events, and resolution of comorbid conditions associated with the use of the BariClip device in adult patients with severe obesity in Jordan

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN98465849
Enrollment
50
Registered
2023-02-16
Start date
2023-03-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and its associated disorders Nutritional, Metabolic, Endocrine Obesity

Interventions

Laparoscopic vertical clip gastroplasty with the BariClip device. In the procedure, the clip is placed parallel to lesser curvature to separate the stomach into a restricted medial segment where food

Sponsors

Jordan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18 – 65 years 2. Male or female 3. BMI >40 kg/m² and BMI >30 kg/m² with at least one comorbid condition (hypertension [HTN], type 2 diabetes [DT2], sleep apnea) 4. Willingness to comply with the substantial lifelong dietary restrictions required by the procedure (written consent form) 5. History of obesity for at least 5 years 6. History of failure with dieting methods 7. Willingness to follow protocol requirements including signed consent, routine follow-up schedule, completing quality of life (QOL) questionnaires, completing laboratory tests, completing diet and behavior modification counseling 8. Residing within a reasonable distance from an investigating center and able to travel to the investigator to complete all routine follow-up visits

Exclusion criteria

Exclusion criteria: 1. Surgery or treatment represents an unreasonable risk to the subject 2. Patient history of inflammatory disease of the gastrointestinal (GI) tract (including ulceration, duodenal ulceration, grade 4 esophagitis, specific inflammation such as Crohn’s disease or ulcerative colitis) 3. Severe cardiopulmonary disease or other serious organic disease 4. Severe coagulopathy, upper gastrointestinal (UGI) bleeding conditions, such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia 5. Congenital or acquired anomalies of the GI 6. Severe hiatal hernia (>3 cm) 7. Pregnant or has the intention of becoming pregnant in the next 12 months 8. Alcohol or drug addiction, active smoker 9. Mental retardation or emotional instability, or psychological characteristics which, in the opinion of the investigators, make the subject a poor candidate for clip surgery 10. Previous esophageal, gastric surgery, hepatectomy, splenectomy 11. Previous endoscopic procedure for obesity 12. Patient under GLP1 medication or weight loss drug 13. Diabetes patient under treatment for gastroparesis 14. Previous bariatric surgery, intestinal obstruction, or adhesive peritonitis 15. Patient history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma, or other autoimmune connective tissue disorder 16. Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the Clip clinical trial

Design outcomes

Primary

MeasureTime frame
Percent Excess Weight Loss (%EWL) defined as weight loss divided by baseline excess weight. Excess weight will be determined from ideal body weight based on a BMI of 24.9 for normal adults (Center for Disease Control [CDC]) at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months post-implantation.

Secondary

MeasureTime frame
1. Absolute weight loss over 60 months, defined simply as the total weight loss for the follow-up period 2. Total change in weight (TWL%) defined as (preoperative (preop) weight – follow up weight)/(preop weight) X 100%, measured at 12, 36 and 60 months 3. Total change in BMI (TBMIL%) defined as (preoperative (preop) BMI – follow up BMI)/(preop BMI) X 100%, measured at 12, 36 and 60 months 4. Plasma glucose levels, HbA1c levels, and resolution of T2DM (% of patients, defined as HbA1C<6) in diabetic patients measured annually over 5 years

Countries

Jordan

Contacts

Public ContactAshraf Haddad
Ashraf.haddad@gbmc-jo.com+962 (0)7 9557 2195

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026